Relation Between Protein 13 and Gestational Hypertensive Disorder

Completed

• Conditions: Gestational Hypertension
• Interventions: Diagnostic Test: Estimation of Protein 13

• Registration Number: NCT05517512
• Lead Sponsor: Benha University

Brief Summary

the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy protein 13 (PP13). The same evaluation was repeated on the 6th, 24th, 32nd, and 36th gestational week (GW). Twenty non-pregnant women gave samples as a negative control group.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-12
• Primary Completion: 2021-03-14
• Study Completion: 2022-03-19
• Status Verified: 2022-08
• Study First Submitted: 2022-08-09
• Study First Submitted QC: 2022-08-24
• Last Update Submitted: 2022-08-24
• Study First Posted: 2022-08-26
• Last Update Posted: 2022-08-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 138

Inclusion Criteria

• Normotensive women who attended the clinic with a one-missed period (T0)

Read More

Exclusion Criteria

• History of essential hypertension (HTN)
• renal diseases
• hepatic diseases
• cardiac diseases
• metabolic syndrome
• body mass index (BMI) >35 kg/ m2
• congenital heart diseases

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Gestational Hypertension	Estimation of Protein 13	-
Pre Eclampsia	Estimation of Protein 13	-
Control	Estimation of Protein 13	-

Primary Outcome Measures

Name	Time	Method
Serum biomarkers and GHD	9 months	The primary outcome is the ability of early ELISA estimation of biomarkers for prediction of GHD

Trial Locations

Locations (1)

Banha University; 🇪🇬 Banhā, El- Qalyobia, Egypt